Immunotherapy for Prostate Cancer: Treatments for the “Lethal” Phenotype – DocWire News

Urol Clin North Am. 2020 Nov;47(4):469-474. doi: 10.1016/j.ucl.2020.07.007. Epub 2020 Sep 10.

ABSTRACT

Multiple immunologic platforms have provided minimal impact in patients with metastatic castration-resistant prostate cancer, necessitating that novel approaches continue to be developed. Although checkpoint inhibitors have been largely ineffective, there remain small cohorts of patients who have durable responses but lack the conventional indicators for response to this class of drugs, that is, high mutational burden or significant genomic alterations, as seen in other solid tumors. This article presents an update on the evolution of immunotherapeutics that target a more lethal form of prostate cancer and provides the groundwork for future considerations as to how this field should proceed.

PMID:33008497 | DOI:10.1016/j.ucl.2020.07.007